Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced its participation in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022. This event will feature the management team discussing innovations in precision cancer therapies and diagnostics through the Personalis NeXT Platform, which analyzes the full spectrum of human genes and immune system data.
Personalis' Clinical Laboratory is GxP-aligned and certified, emphasizing clinical accuracy and efficiency.
Personalis, Inc. (PSNL) reported Q2 2022 results, with revenues of $18.2 million, down from $21.7 million in Q2 2021. Revenue from biopharma customers rose by 74% to $14.2 million, boosted by $6.8 million from Natera. VA MVP revenues fell sharply to $4.0 million from $13.5 million year-over-year. The company incurred a net loss of $27.5 million and anticipates total 2022 revenues between $62.0 million to $67.0 million. Notably, cash reserves were strong at $233.5 million as of June 30, 2022.
Personalis, Inc. (Nasdaq: PSNL) has filed a lawsuit against Foresight Diagnostics Inc. for infringing its U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394, central to its tumor-informed molecular residual disease (MRD) testing innovations. This legal action seeks both injunctive relief and monetary damages. Personalis emphasizes its long-standing expertise in whole genome sequencing, asserting that its NeXT Personal MRD solution represents a significant advancement in cancer detection, achieving unmatched sensitivity in identifying residual cancer cells.
Personalis, Inc. (NASDAQ: PSNL) will release its second quarter 2022 financial results on August 3, 2022. The company will also host a conference call and webcast at 2:00 p.m. PT to discuss financial outcomes and recent developments. Interested participants can register for the call via the provided link and access the live webinar on the company's website. Personalis is recognized for its advancements in cancer genomics, playing a pivotal role in precision oncology through the Personalis NeXT Platform®.
Personalis, Inc. (NASDAQ: PSNL) has added a new patent to its molecular residual disease (MRD) IP portfolio, issued on January 2013, focusing on tumor detection through whole genome sequencing. The newly granted US Patent No. 11,384,394 enhances the NeXT Personal™ platform, allowing for highly sensitive measurement of tumor burden. This patent strengthens Personalis' position in advanced genomic analysis with 21 issued patents and over 30 pending applications related to cancer detection and genomic sequencing. The approach could lead to earlier detection of cancer recurrence and improved treatment options.
Personalis, Inc. (Nasdaq: PSNL) reported Q1 2022 financial results with revenue of $15.2 million, down from $20.9 million in Q1 2021. Revenue from biopharma customers increased by 53% to $11.7 million, including $4.1 million from Natera. Revenue from the VA MVP dropped to $3.5 million from $13.2 million in the prior year. The company expects full-year 2022 revenue between $62.0 million and $67.0 million, with a projected net loss of $110.0 million to $115.0 million.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in upcoming investor conferences to showcase its advancements in cancer genomics. The company will present at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 6:20 p.m. ET in Las Vegas, and at the UBS Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET in New York. Personalis is committed to enhancing precision cancer therapies through its innovative NeXT Platform, which evaluates nearly 20,000 human genes from a single sample.
Evaxion Biotech and Personalis announced a collaboration utilizing the ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy of Evaxion's cancer immunotherapy EVX-01. The trial will study the combination of EVX-01 with KEYTRUDA in metastatic melanoma patients. Evaxion's AI tool PIONEER is expected to enhance treatment precision by targeting significant cancer mutations. The partnership aims to improve patient outcomes and advance companion diagnostics. Both companies leverage advanced AI and genomic technologies to boost cancer therapy development.
Personalis, Inc. (Nasdaq: PSNL) announced the appointment of James Azzaro as the Vice President of Diagnostic Sales, a new role aimed at enhancing the company's clinical market presence. With over 20 years in oncology diagnostics, Azzaro is set to lead efforts to grow clinical test volumes and secure reimbursement for the NeXT Dx™ and NeXT Personal™ tests. CEO John West expressed confidence in Azzaro's ability to drive commercial success in partnering with healthcare systems and oncologists across the United States.
Personalis, Inc. (NASDAQ: PSNL) will release its Q1 2022 financial results on May 4, 2022, at 2:00 p.m. PT. Following the release, a conference call will occur to discuss financial results and highlights. Interested participants can join via phone or through a live webcast on the company's website.
Personalis specializes in advanced genomics for cancer treatments, utilizing the Personalis NeXT Platform to provide comprehensive genetic insights from single samples, enhancing precision cancer therapies.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
